Company: Threshold Pharmaceuticals [1]
Starting stock price: $3.41
Ending stock price: $0.53
Percent Change: -84.46%
Details: Threshold had a tough time of it in 2006, and the situation didn't improve in 2007 when the company halted a Phase II trial of glufosfamide for small cell lung cancer after it found that patients weren't responding to the drug. Just two weeks later Threshold chopped its 44-person workforce down to 32, concentrating on its hypoxia-activated prodrug program and the ongoing clinical trials of glufosfamide for pancreatic cancer and Phase II for ovarian cancer. Earlier this year the company said the pancreatic cancer trial would continue, but the ovarian cancer trial has been abandon due to lack of efficacy.
More News:
Threshold slashes staff in effort to cut burn rate. Report [2]
Threshold halts lung cancer study. Report [3]
Threshold delays release of glufosfamide analysis. Report [4]
Threshold slashes staff in wake of quarterly loss. Report [5]
Threshold shares drop after Phase III suspension. Report [6]
Links:
[1] http://www.thresholdpharm.com/
[2] http://www.fiercebiotech.com/story/threshold-slashes-staff-effort-cut-burn-rate/2007-10-30
[3] http://www.fiercebiotech.com/story/threshold-halts-lung-cancer-study/2007-10-12?utm_medium=nl&utm_source=link
[4] http://www.fiercebiotech.com/story/threshold-delays-release-of-glufosfamide-analysis/2006-11-29
[5] http://www.fiercebiotech.com/story/threshold-slashes-staff-in-wake-of-quarterly-loss/2006-08-10
[6] http://www.fiercebiotech.com/story/threshold-shares-drop-after-phase-iii-suspension/2006-05-12
[7] http://www.fiercepharma.com/special-reports/sonus-pharmaceutical-worst-pharma-stocks-2007
[8] http://www.fiercepharma.com/special-reports/worst-pharma-stocks-2007
[9] http://www.fiercepharma.com/special-reports/hana-biosciences-worst-pharma-stocks-2007